Scarica l'app Stockscreener
5.0955
1.71%
0.0855
Dopo l'orario di chiusura:
5.10
0.0045
+0.09%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$5.01
Aprire:
$5.19
Volume 24 ore:
14,364
Relative Volume:
1.57
Capitalizzazione di mercato:
$70.92M
Reddito:
$57.94M
Utile/perdita netta:
$-2.34M
Rapporto P/E:
-30.59
EPS:
-0.1666
Flusso di cassa netto:
$3.82M
1 W Prestazione:
-3.49%
1M Prestazione:
-0.87%
6M Prestazione:
-13.64%
1 anno Prestazione:
-20.88%
Intervallo 1D:
$5.05
$5.2691
Intervallo di 1 settimana:
$4.85
$5.41
Portata 52W:
$4.83
$8.74
Champions Oncology Inc Stock (CSBR) Company Profile
Nome
Champions Oncology Inc
Settore
Industria
Telefono
410-369-0365
Indirizzo
855 N. WOLFE STREET, BALTIMORE, NJ
Compare CSBR vs VRTX, REGN, ARGX, MRNA, RVMD
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
CSBR
Champions Oncology Inc
|
5.0955 | 69.73M | 57.94M | -2.34M | 3.82M | -0.1666 |
VRTX
Vertex Pharmaceuticals Inc
|
514.56 | 132.08B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
793.26 | 83.15B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.04 | 62.71B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
136.62 | 54.14B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.35 | 44.51B | 742.00K | -1.37B | -1.07B | -7.0731 |
Champions Oncology Inc Stock (CSBR) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2024-09-12 | Aggiornamento | Craig Hallum | Hold → Buy |
| 2019-11-18 | Iniziato | The Benchmark Company | Speculative Buy |
Champions Oncology Inc Borsa (CSBR) Ultime notizie
Champions Oncology Q1 Results: Adj. EPS up 400% to $0.05 - scanx.trade
Champions Oncology (CSBR) Q1 Fiscal 2027 Earnings Call: Revenue Up 9%, Services Margin Reaches 51% - TradingKey
Champions Oncology Q1 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Champions Oncology tops Q1 2027 estimates, shares slip - Investing.com
Champions Oncology earnings beat by $0.06, revenue topped estimates - Investing.com
Champions Oncology reports Q1 revenue $15.2M, adjusted EBITDA $0.7M and oncology services margin 51% - TradingView
CSBR: Revenue up 8.8% to $15.2M, oncology margin at 51%, adjusted EBITDA $671K, net loss $426K - TradingView
Champions Oncology, Inc. Reports Earnings Results for the First Quarter Ended July 31, 2026 - marketscreener.com
Champions Oncology posts better-than-expected Q1, but shares edge lower on higher costs - Investing.com
CHAMPIONS ONCOLOGY ($CSBR) Releases Q1 2027 Earnings - quiverquant.com
Champions Oncology Reports Revenue of $15.2 Million - Weatherford Democrat
Oracle, Adobe, Copart and more set to report earnings Thursday By Investing.com - Investing.com Australia
Oracle, Adobe, Copart and more set to report earnings Thursday - Investing.com
CSBR Q1'26 Earnings: EPS estimate is (0.01) USD - TradingView
Champions Oncology to Announce First Quarter Financial Results on Thursday, September 10, 2026 - Black Hills Pioneer
A cancer research company will report results Sept. 10 - Stock Titan
CSBR - Finviz
Champions Oncology Expands Integrated Radiopharmaceutical Development Platform with In-House SPECT/CT Imaging - New Castle News
New imaging follows cancer treatments inside tumors—and links uptake to response - Stock Titan
Anixa Biosciences Inc. (ANIX) Peer Comparison – Compare with Others - Value Research
Champions (CSBR) Range: Finishes 4.86% Up at $5.18 in the Latest Session; Price Setup: the Near-Term Reference Band Stretches From $4.92 to $5.44 in the Available RecordHidden Order - vinanet.vn
North-America Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Japan Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Rest-Of-Asia-Pacific Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Latin-America Humanized Mouse and Rat Model Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
Comedian Michael Kosta Headlines Karmanos Comedy Champions on New October Date, Hosted by 101 WRIF's Jade Springart - PR Newswire
Precision Trading with Champions Oncology Inc. (CSBR) Risk Zones - Stock Traders Daily
OSTX Stock Price and Chart — AMEX:OSTX - TradingView
Manulife China Bank Life Champions Early Health Action and Financial Planning at The Art of Longevity - Mindanao Times
Residential Social Vulnerability Associated With Worse Survival Among Black Women With Epithelial Ovarian Cancer - The ASCO Post
China Patient Derived Xenografts/PDX Models Market Size, Share,Trends, Growth Analysis Report, 2030 - MarketsandMarkets
KLRS Stock Price and Chart — NASDAQ:KLRS - TradingView
NMAD Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Oil Prices Rise as Iran Draft Plan Proposes Barring U.S. and Israel From Strait of HormuzAnnual Report - Vinanet
Technical Reactions to CSBR Trends in Macro Strategies - Stock Traders Daily
Champions Oncology Inc (CSBR) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Champions Oncology (NASDAQ:CSBR) Stock Price Crosses Below 200 Day Moving AverageHere's Why - MarketBeat
Champions Oncology (CSBR) Pulls Back 2.7% as Shares Test Support Near $5.33Sweep Order Flow - vinanet.vn
Champions Oncology, Inc. Revenue Breakdown – NASDAQ:CSBR - TradingView
CSBR Stock Dips Post Q4 Earnings Despite Record Revenue Growth, AI Push - theglobeandmail.com
Champions Oncology Inc (CSBR) (Q4 2026) Earnings Call Highlights: Record Revenue and Positive ... By GuruFocus - Investing.com Canada
AgomAb Therapeutics (AGMB) Holds Steady Near Resistance as Biotech Sector Shows Mixed SentimentHead and Shoulders - vinanet.vn
Champions Oncology Inc (CSBR) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Champions Oncology Inc (CSBR) Institutional Confidence - TradingKey
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue By Investing.com - Investing.com Nigeria
Champions Oncology Inc (CSBR) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Champions Oncology Q4 Earnings Call Highlights - Yahoo Finance
Earnings call transcript: Champions Oncology posts record Q4 2026 revenue - Investing.com
CSBR: Record revenue and positive Adjusted EBITDA achieved, with strong core services growth and margin gains - TradingView
CHAMPIONS ONCOLOGY, INC. FY 2026: Revenue $59.43M, EPS ($0.08) — 10-K Summary - TradingView
CSBR: Revenue up 4.4% to $59.4M, but net loss of $1.2M driven by higher R&D and operating costs - TradingView
Champions Oncology Inc Azioni (CSBR) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
3.04%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):